# Thymosin Alpha-1: A Field Guide to the Thymic Immune Peptide

> Thymosin Alpha-1 is a 28-amino-acid thymic immune peptide studied as a vaccine adjuvant and immune-restorative across four decades. A cited, plain-English digest of what the studies actually found.

A naturalist's reading of the published record — what the studies measured, where the evidence is strong, and the places the light never quite reached. Every number cited.

## Start here

Thymosin Alpha-1 is a small protein your body already makes. It is a 28-amino-acid peptide (a short chain of the building blocks that make up proteins) that the thymus — a small immune-training gland behind the breastbone — releases to help the immune system work. Researchers study it because its level falls as people age, and because giving it back appears to help an aging or worn-down immune system respond better. The clearest finding, repeated since the 1980s, is that older adults who got it alongside a flu vaccine made a stronger antibody response than those who did not [8]. Other studies have looked at hepatitis, sepsis, and COVID-19, with mixed results. It is generally easy to tolerate; the main reported downside is a sore injection spot. It is not a muscle-building peptide, and it is not approved for sale in the United States. What people report — including the disappointments — is on [the effects page](/effects).

## What the Thymosin Alpha-1 record actually shows

Thymosin Alpha-1 (also called thymalfasin, its drug name, and abbreviated Tα1) was first pulled out of calf thymus tissue and sequenced by Allan Goldstein's group in 1977 [1]. It is not an anabolic, growth, or performance compound — it does not build muscle. It is an *immunomodulator*: a molecule that adjusts how the immune system behaves, dialing a weak response up and a runaway one down.

The mechanism is now reasonably well mapped. Thymosin Alpha-1 signals through Toll-like receptors (TLR2 and TLR9 — sensors on immune cells that normally detect pathogens) on dendritic cells (the immune system's scouts, which show captured material to other cells), pushing them to mature and prime T cells. In parallel it activates an enzyme called IDO that generates a calming, regulatory arm [5]. That dual action — wake up the defense, but keep it from overreacting — is the through-line of the whole literature.

## The strongest signal: an aging immune system, restored

The most consistent human finding sits in the vaccine-and-aging corner. In a double-blind, placebo-controlled trial, elderly men given Thymosin Alpha-1 (studied at 900 μg subcutaneously twice weekly for four weeks) alongside an influenza vaccine produced significantly higher post-vaccine antibody titers than placebo [8]. Earlier laboratory work had already shown the effect was larger in cells from older donors than younger ones — exactly where an immune boost is most needed [10]. A 2007 review pulled the elderly-vaccine trials together and found the same direction of effect across cohorts [9], and a 2025 review framed the whole compound around reversing *immunosenescence*, the gradual decline of immune function with age [16].

This is the [thymosin alpha 1 benefits](/benefits) most grounded in real human data, and the lens this site reads the rest of the record through.

## Where the evidence is honest about its limits

Two facts keep the picture sober. First, **Thymosin Alpha-1 is not FDA-approved in the United States.** The synthetic drug thymalfasin is approved in roughly 35 other countries for chronic hepatitis B and as an immune adjuvant, but in the US it exists only in investigational and compounding contexts [4].

Second, the largest and most rigorous trial came back empty. The phase-3 TESTS trial enrolled 1,106 adults with sepsis across 22 centres and found **no significant difference** in 28-day mortality between Thymosin Alpha-1 (23.4%) and placebo (24.1%) — a hazard ratio of 0.99 [3]. That null result tempers earlier, smaller, more positive studies, and it is exactly the kind of caveat this field guide keeps in view. The full [Thymosin Alpha-1 research](/research) and the [Thymosin Alpha-1 references](/references) lay the studies out in order.

---

A naturalist's dive-log through four decades of the Thymosin Alpha-1 literature — each observation lit one at a time and cited to source, the null results left in plain view, with no clinic in the dark behind it and nothing here dispensed or sold.